Pfizer is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech. Have the good days finally come to an end ...
MyChesCo on MSN
Arbutus Reports Major Advances in HBV Candidate as Litigation Against Moderna, Pfizer Builds Toward Trial
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) reported third quarter 2025 financial results and released new ...
A significant development emerged on November 13 when Pfizer announced it had sold 54.7% of its stake in BioNTech, retaining only $163.5 million worth of shares. This move marks a substantial shift in ...
BioNTech formally launched its public takeover bid on October 22, 2025, offering CureVac shareholders approximately $5.46 per share in BioNTech American Depositary Shares. The exchange ratio includes ...
SC lawmakers advanced a bill that would require a disclaimer for COVID-19 vaccinations. Physicians have broadly encouraged ...
(Nov 19): Hyundai Motor Co chief executive officer José Muñoz said the South Korean automaker received an apology from the US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback